[Editorial] Lymphoma in the BiTE era

The development of bispecific antibodies to treat B-cell non-Hodgkin lymphoma has marked a substantial advance that offers new hope for patients. The bispecific T-cell engager epcoritamab joins a growing list of treatments for several lymphoma settings, with encouraging results presented at the American Society of Hematology (ASH) annual meeting. In the EPCORE FL-1 trial, 488 patients with relapsed or refractory follicular lymphoma received lenalidomide and rituximab with and without epcoritamab, with a positive result for the dual primary endpoint of overall response rate and progression-free survival leading to this combination being approved by the US Food and Drug Administration (FDA) on Nov 18, and it joins mosunetuzumab as a bispecific antibody treatment option for this disease setting.